International journal of nanomedicine

Using Nanotechnology to Deliver Immune Treatments Together for Ovarian Cancer: Possible Benefits and Challenges

Abstract

Nanocarrier-based co-delivery strategies may enhance treatment effectiveness in ovarian cancer by targeting both tumor cells and the immune microenvironment.

  • Co-delivery of chemotherapeutics with immune checkpoint inhibitors may improve antigen expression and T-cell infiltration in tumors.
  • Nanoparticle delivery of immunostimulatory cytokines could activate the immune response locally while minimizing systemic toxicity.
  • Gene-editing nanotherapies are emerging as a potential approach for improving treatment outcomes.
  • Early clinical trial data indicate that nanocarrier systems can effectively reprogram myeloid cells in ovarian cancer.
  • Challenges remain regarding safety, synthesis, and regulatory issues for these nanotechnology-assisted therapies.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors report no conflicts of interest in this work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free